Saikosaponin-d increases the radiosensitivity of smmc-7721 hepatocellular carcinoma cells by adjusting the g0/g1 and g2/m checkpoints of the cell cycle

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Wang, Bao Feng ^a   Dai, Zhi Jun ^a   Wang, Xi Jing ^a   Bai, Ming Hua ^a   Lin, Shuai ^a   Ma, Hong Bing ^a   Wang, Ya Li ^a   Song, Ling Qin ^a   Ma, Xiu Long ^a   Zan, Ying ^a   Min, Wei Li ^a   Cheng, Yan An ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SAIKOSAPONIN D;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL CYCLE; CELL GROWTH; CELL VIABILITY; DRUG EFFECT; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; RADIATION EXPOSURE; RADIOSENSITIVITY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; OLEANOLIC ACID; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION-SENSITIZING AGENTS; RNA, MESSENGER; SAPONINS; TUMOR SUPPRESSOR PROTEIN P53; X-RAYS;

EID: 84885369303     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-263     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Inflammatory tumour micro- environment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010, 52:370-9.
3. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma:a prospective study of 377 patients over 10years. Ann Surg 2001, 234:63-70. 10.1097/00000658-200107000-00010, 1421949, 11420484.
4. Lee H, Park HC, Lee JA, Kim SW, Yoo BC, Koh KC, Lee JH, Choi MS, Gwak GY, Paik SW, Lim Do H. The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with smallhepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol 2013, 36:162-6. 10.1097/COC.0b013e3182438dae, 22391433.
5. Dewas S, Mirabel X, Kramar A, Jarraya H, Lacornerie T, Dewas-Vautravers C, Fumagalli I, Lartigau T. Stereotactic body radiation therapy for liver primary and metastases: the Lille experience. Cancer Radiother 2012, 16:58-69. 10.1016/j.canrad.2011.06.005, 22209710.
6. Wardman P. Chemical radiosensitizers for Use in radiotherapy. Clin Oncol 2007, 19:397-417.
7. Girdhani S, Bhosle SM, Thulsidas SA, Kumar A, Mishra KP. Potential of radiosensitizing agents in cancer chemo-radiotherapy. J Cancer Res Ther 2005, 1:129-31. 10.4103/0973-1482.19585, 17998642.
8. Lu CN, Yuan ZG, Zhang XL, et al. Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway. Int Immunopharmacol 2012, 14:121-126. 10.1016/j.intimp.2012.06.010, 22728095.
9. Hattori T, Nishimura H, Kase Y, Takeda S. Saireito and saikosaponin D prevent urinary protein excretion via glucocorticoid receptor in adrenalectomized WKY rats with heterologous-phase anti-GBM nephritis. Nephron Physiol 2008, 109:19-27.
10. Fan J, Li X, Li P, et al. Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 2007, 85:189-95. 10.1139/O07-010, 17534399.
11. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG, Li ZF. Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats. World J Gastroenterol 2007, 13:557-63.
12. Wang BF, Cheng YA, Dang SS. Angiogenesis inhibitory effect of saikosaponin-d on chicken embryo. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009, 29:425-429.
13. Hsu YL, Kuo PL, Chiang LC, Lin CC. Involvement of p53, nuclear factor kappaB and Fas/Fas ligand in induction of apoptosis and cell cycle arrest by saikosaponin d in human hepatoma cell lines. Cancer Lett 2004, 213:213-221. 10.1016/j.canlet.2004.03.044, 15327837.
14. Wang Q, Zheng XL, Yang L, et al. Reactive oxygen species-mediated apoptosis contributes to chemosensiti- zation effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res 2010, 29:159. 10.1186/1756-9966-29-159, 3006358, 21143894.
15. He SX, Luo JY, Zhao G, Xu JL, Wang YL, Fu H, Dong L. Effect of saikosaponins-d on cyclooxygenase-2 expression of human hepatocellular carcinomacell line SMMC-7721. Zhonghua Gan Zang Bing Za Zhi 2006, 14:712-4.
16. Wong VK, Zhang MM, Zhou H, Lam KY, Chan PL, Law CK, Yue PY, Liu L. Saikosaponin-d enhances the anticancer potency of TNF-α via overcoming its undesirable response of activating NF-kappa B signalling in cancer cells. Evid Based Complement Alternat Med 2013, 2013:745295. 3610377, 23573150.
17. Yang W, Sun T, Cao J, Fan S. Hypoxia-inducible factor-1α downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and enhances radiosensitivity in chemical hypoxic human hepatoma SMMC-7721 cells. Cancer Biother Radiopharm 2011, 26:565-71. 10.1089/cbr.2011.0955, 21950556.
18. Ji Z, Yang G, Shahzidi S, Tkacz-Stachowska K, Suo Z, Nesland JM, Peng Q. Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Lett 2006, 244:182-9. 10.1016/j.canlet.2005.12.010, 16427735.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-8. 10.1006/meth.2001.1262, 11846609.
20. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994, 226:1821-1828.
21. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-11.
22. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992, 89:7491-5. 10.1073/pnas.89.16.7491, 49736, 1323840.
23. Basu A, Haldar S. The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998, 4:1099-109. 10.1093/molehr/4.12.1099, 9872359.
24. Welsh S, Williams R, Kirkpatrick L, Paine-Murrieta G, Powis G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 a. Mol Cancer Ther 2004, 3:233-44.
25. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, Powis G. Molecular mechanisms for the activity of PX-478, an anti tumor inhibitor of the hypoxia-inducible factor-1 α. Mol Cancer Ther 2008, 7:90-100.